It's working overtime.
Pancreatic cancer is mentioned in other PRs, citing the number of cases annually.
From 12/1/15 PR: “Receiving Orphan Drug Designation from the EMA is another significant step forward for Advaxis as we continue to advance ADXS-HER2,” said Daniel J. O'Connor, CEO of Advaxis. “We recently initiated our first-in-human study of our lead Lm Technology™ immunotherapy product for HER2 expressing solid tumors and we hope to expand that trial into four HER2 expressing tumor types, including breast, gastric, esophageal and osteosarcoma.”
Maybe his original ID got banned.
"If you don't believe you can look at all the 8,000 shares purchases I made." I doubt he could purchase 8 shares at a time.